IMPACT CKD model projects up to 16.5% of the population across eight countries to suffer from chronic kidney disease by 2032

A new modelling analysis by AstraZeneca, IMPACT CKD, forecasts up to 16.5% of the population across eight countries will suffer from chronic kidney disease (CKD) by 2032, including a rise of up to 59.3% in advanced-stage.¹ Presented at the 2024 ISN World Congress of Nephrology (WCN’24) in Buenos Aires, the study highlights an urgent and growing global health crisis with profound economic and environmental implications.¹ IMPACT CKD is the first study to examine and forecast the vast, multi-dimensional impact of CKD over a 10-year time horizon across eight countries — the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia.¹

The research estimates nearly 125 million people across these countries will suffer from advanced CKD by 2032, marking a 25% increase since 2022 when the model began.¹ The economic toll of renal replacement therapy, including dialysis and transplant, is anticipated to reach approximately $186 billion, and dialysis requirements are expected to surge by over 75%, contributing significantly to healthcare's carbon footprint — equivalent to adding approximately 17.3 million cars' worth of CO2 emissions.¹

Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca, highlights: “Our modelling emphasises the enormous impact CKD could have on patients, economies and the environment. But this future is not inevitable. At AstraZeneca, we are committed t…